Cabaletta Bio’s autologous anti-CD19 chimeric antibody receptor T cells designed to deplete CD19+ B cells were granted FDA orphan designation as a treatment of Idiopathic Inflammatory Myopathies, or IIM according to a post to the agency’s website. (
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CABA:
- FDA instructs drugmakers to add T cell malignancy risk info to CAR-T labels
- Biotech Alert: Searches spiking for these stocks today
- Cabaletta Bio receives additional FDA Fast Track Designations for CABA-201
- Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally
